Last reviewed · How we verify
Etavopivat Tablets High dose
Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase antioxidant defenses and reduce hemolysis in red blood cells.
Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase antioxidant defenses and reduce hemolysis in red blood cells. Used for Sickle cell disease, Beta-thalassemia.
At a glance
| Generic name | Etavopivat Tablets High dose |
|---|---|
| Also known as | FT-4202 |
| Sponsor | Forma Therapeutics, Inc. |
| Drug class | Nrf2 activator |
| Target | Nrf2 (NFE2L2) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Rare Blood Disorders |
| Phase | Phase 3 |
Mechanism of action
Etavopivat is an Nrf2 activator that enhances the expression of antioxidant response elements and cytoprotective genes in erythrocytes. By boosting cellular antioxidant capacity, it reduces oxidative stress-induced hemolysis, particularly in conditions like sickle cell disease where red blood cells are vulnerable to oxidative damage. This mechanism helps stabilize red blood cell integrity and improve hemoglobin levels.
Approved indications
- Sickle cell disease
- Beta-thalassemia
Common side effects
- Hyperuricemia
- Elevated uric acid levels
- Gout
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |